Comparative Impact of Olanzapine and Aripiprazole on the Development of Metabolic Syndrome in Patients with Psychiatric Disorders
Olanzapine and Aripiprazole on the Metabolic Syndrome in Psychiatric Disorders Patients
DOI:
https://doi.org/10.54393/pjhs.v6i12.3084Keywords:
Antipsychotics, Aripiprazole, Metabolic Syndrome, OlanzapineAbstract
To compare the development of metabolic syndrome in patients treated with olanzapine versus aripiprazole. Methods: This prospective observational study was conducted at Shahida Islam Medical College and Hospital over six months (June–November 2024). Patients with psychiatric disorders who had received either olanzapine or aripiprazole for ≥6 months were included. Metabolic syndrome was assessed using the International Diabetes Federation (IDF) criteria. Patients were divided into two treatment groups: olanzapine (n=104) and aripiprazole (n=104). Data were analyzed using SPSS version 23.0. Chi-square, Fisher’s exact, independent t, and Mann-Whitney U tests were applied where appropriate, with p<0.05 considered significant. Results: A total of 208 patients were analyzed (mean age: olanzapine 46.42 ± 9.21 years; aripiprazole 47.44 ± 8.78 years). Metabolic syndrome prevalence was significantly higher in the olanzapine group (45.2%) compared to the aripiprazole group (30.8%) (p<0.05). Patients on olanzapine had higher waist circumference, BMI, and blood pressure. Metabolic abnormalities were also more frequent with olanzapine: diabetes (34.0% vs. 15.6%), hyperlipidemia (25.5% vs. 9.4%), and microalbuminuria (25.5% vs. 6.3%). Conclusions: Aripiprazole demonstrated a significantly lower risk of metabolic syndrome and better metabolic outcomes than olanzapine, highlighting the need for careful monitoring and the consideration of safer alternatives in clinical practice.
References
Carli M, Kolachalam S, Longoni B, Pintaudi A, Baldini M, Aringhieri S et al. Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical Differences. Pharmaceuticals. 2021 Mar; 14(3): 238. doi: 10.3390/ph14030238.
Umakanth M and Gadambanathan T. Metabolic Syndrome, and Cardiovascular Risk among Mentally Ill Patients. Journal of Biosciences and Medicines. 2018 Aug; 6(08): 72. doi: 10.4236/jbm.2018.68006.
Akinola PS, Tardif I, Leclerc J. Antipsychotic-Induced Metabolic Syndrome: A Review. Metabolic Syndrome and Related Disorders. 2023 Aug; 21(6): 294-305. doi: 10.1089/met.2023.0003.
Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why Olanzapine Beats Risperidone, Risperidone Beats Quetiapine, and Quetiapine Beats Olanzapine: An Exploratory Analysis of Head-To-Head Comparison Studies of Second-Generation Antipsychotics. American Journal of Psychiatry. 2006 Feb; 163(2): 185-94. doi: 10.1176/appi.ajp.163.2.185.
Silva DG, Kanazawa LK, Vecchia DD. Schizophrenia: Effects of Aripiprazole in Metabolic Syndrome. Brazilian Journal of Pharmaceutical Sciences. 2019 Nov; 55: e17840. doi: 10.1590/s2175-97902019000217840.
Doménech-Matamoros P. Influence of the Use of Atypical Antipsychotics in Metabolic Syndrome. Revista espanola de sanidad penitenciaria. 2020 Jul; 22(2): 80. doi: 10.18176/resp.00014.
Gupta B, Chee KS, Neo LQ, Tang C, Hariram J, Tan GC et al. Effect of Aripiprazole as an Adjunct to Atypical Antipsychotics on Weight and Metabolic Profile: A 12-Week Open-Label Trial. Therapeutic Advances in Psychopharmacology. 2021 Oct; 11: 20451253211046765. doi: 10.1177/20451253211046765.
Liu S, Yuan X, Ye X, Zhang Y, Zhao L, Zhou K. Efficacy of Aripiprazole Combined with Olanzapine for Hospitalized Male Patients with Schizophrenia and Its Effect on Metabolic Syndrome. Sichuan Mental Health. 2024: 226-31.
Wang KC, Chan HY, Yang WS, Huang YM, Ho YF, Hwang TJ. Cardiometabolic Biomarkers and Comorbid Metabolic Syndrome in Schizophrenia: A Cross-Sectional Study of Long-Term Clozapine/Olanzapine Users. Asian Journal of Psychiatry. 2024 Dec; 102: 104244. doi: 10.1016/j.ajp.2024.104244.
Samyukta KJ, Shivson D, KantiPuDi SJ. Effect of Olanzapine on Metabolic Syndrome A One-Year Follow-Up Study. Journal of Clinical and Diagnostic Research. 2020 Jun; 14(6). doi: 10.7860/JCDR/2020/44521.13773.
Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N et al. Global and Regional Diabetes Prevalence Estimates for 2019 and Projections for 2030 And 2045: Results from the International Diabetes Federation Diabetes Atlas. Diabetes Research and Clinical Practice. 2019 Nov; 157: 107843. doi: 10.1016/j.diabres.2019.107843.
Jeong SH, Lee NY, Kim SH, Chung IW, Youn T, Kang UG et al. Long-term Evolution of Metabolic Status in Patients with Schizophrenia Stably Maintained on Second-Generation Antipsychotics. Psychiatry Investigation. 2018 Jun; 15(6): 628. doi: 10.30773/pi.2018.01.18.1.
Kornetova EG, Kornetov AN, Mednova IA, Goncharova AA, Gerasimova VI, Pozhidaev IV et al. Comparative Characteristics of the Metabolic Syndrome Prevalence in Patients with Schizophrenia in Three Western Siberia Psychiatric Hospitals. Frontiers in Psychiatry. 2021 Jul; 12: 661174. doi: 10.3389/fpsyt.2021.661174.
Hammoudeh S, Al Lawati H, Ghuloum S, Iram H, Yehya A, Becetti I et al. Risk Factors of Metabolic Syndrome among Patients Receiving Antipsychotics: A Retrospective Study. Community Mental Health Journal. 2020 May; 56(4): 760-70. doi: 10.1007/s10597-019-00537-y.
Ventriglio A, Baldessarini RJ, Vitrani G, Bonfitto I, Cecere AC, Rinaldi A et al. Metabolic Syndrome in Psychotic Disorder Patients Treated with Oral and Long-Acting Injected Antipsychotics. Frontiers in Psychiatry. 2019 Jan; 9: 744. doi: 10.3389/fpsyt.2018.00744.
Hammoudeh S, Ghuloum S, Mahfoud Z, Yehya A, Abdulhakam A, Al-Mujalli A et al. The Prevalence of Metabolic Syndrome in Patients Receiving Antipsychotics in Qatar: A Cross-Sectional Comparative Study. BioMed Central Psychiatry. 2018 Mar; 18(1): 81. doi: 10.1186/s12888-018-1662-6.
L'Italien GJ, Casey DE, Kan HJ, Carson WH, Marcus RN. Comparison of Metabolic Syndrome Incidence among Schizophrenia Patients Treated with Aripiprazole Versus Olanzapine or Placebo. Journal of Clinical Psychiatry. 2007 Oct; 68(10): 1510-6. doi: 10.4088/JCP.v68n1006.
Popović I, Ravanić D, Janković S, Milovanović D, Folić M, Stanojević A et al. Long-Term Treatment with Olanzapine in Hospital Conditions: Prevalence and Predictors of the Metabolic Syndrome. Srpski arhiv za celokupno lekarstvo. 2015; 143(11-12): 712-8. doi: 10.2298/SARH1512712P.
Parabiaghi A, Tettamanti M, D'Avanzo B, Barbato A, GISAS Study Group, Aguglia E et al. Metabolic Syndrome and Drug Discontinuation in Schizophrenia: A Randomized Trial Comparing Aripiprazole Olanzapine and Haloperidol. Acta Psychiatrica Scandinavica. 2016 Jan; 133(1): 63-75. doi: 10.1111/acps.12468.
Park HS, Oh SW, Cho SI, Choi WH, Kim YS. The Metabolic Syndrome and Associated Lifestyle Factors Among South Korean Adults. International Journal of Epidemiology. 2004 Apr; 33(2): 328-36. doi: 10.1093/ije/dyh032.
Koller D, Almenara S, Mejía G, Saiz-Rodríguez M, Zubiaur P, Román M et al. Metabolic Effects of Aripiprazole and Olanzapine Multiple-Dose Treatment in A Randomized Crossover Clinical Trial in Healthy Volunteers: Association with Pharmacogenetics. Advances in Therapy. 2021 Feb; 38(2): 1035-54. doi: 10.1007/s12325-020-01566-w.
Chen CH, Shyue SK, Hsu CP, Lee TS. Atypical Antipsychotic Drug Olanzapine Deregulates Hepatic Lipid Metabolism and Aortic Inflammation and Aggravates Atherosclerosis. Cellular Physiology and Biochemistry. 2018 Oct; 50(4): 1216-29. doi: 10.1159/000494573.
Ono S and Someya T. Lipid Metabolism Disturbances During Antipsychotic Treatment for Schizophrenia. NeuroPsychopharmacotherapy. 2021 Mar: 1-8. doi: 10.1007/978-3-319-56015-1_402-1.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Pakistan Journal of Health Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments
